GIST Pathology and Mutational Testing Update
Dr. Chris Corless In August, the LRG Webcast Series presented “Mutational Analysis of GISTs: How, When and Why.” Dr. Christopher Corless of Oregon Health and Science University (OHSU) presented the hour- long [...]
Please join us for an afternoon of learning about the importance of and the science behind mutational testing with pathologist and GIST specialist, Dr. Christopher Corless of Portland's Oregon Health and Science University. This [...]
Accomplishments—Recent Progress: 1. Using mouse models, successfully attacked GIST with antibodies, essentially telling immune system to eat the cancer cells.
During the past dozen years gastrointestinal stromal tumors have emerged from oncologic obscurity and reached center-stage in the development of targeted therapies for solid tumors. Tyrosine kinase inhibitors (TKIs) like imatinib, sunitinib, and more recently regorafenib, have proven effective in suppressing the growth of metastatic GIST, allowing patients to live far longer than during the previous era of ineffective chemotherapy.